In this report, we demonstrated that activation of β-catenin upregulates Tim-3 in cDC1s, the DC subset specialized in cross-presenting tumor antigens to generate anti-tumor immunity and in determining the efficacy of cancer immunotherapies. This evidence concerns the gene HAVCR2 and neoplasm.